Pharmaceutical Technology

MAY 26, 2023

The immuno-oncology market continues to evolve as treatments establish their presence across different types of cancer, having seen approvals in multiple indications in the past decade. GlobalData separates immuno-oncology treatments into six broad classes, which include bispecific antibodies, cancer vaccines, and cell therapies.

Marketing 264

Marketing Vaccination Vaccine Development 264

BioPharma Reporter

APRIL 8, 2021

Moderna today highlighted the publication of antibody persistence data out to six months following the second dose of its COVID-19 vaccine in The New England Journal of Medicine.

Antibody 96

Antibody Vaccination Vaccine Medicine 96

Pharmaceutical Technology

JUNE 20, 2023

The World Health Organisation (WHO) has granted an emergency use listing (EUL) to SK bioscience’s Covid-19 vaccine, SKYCovione. SKYCovione is a self-assembled nanoparticle vaccine and the 12th Covid-19 vaccine to receive a EUL from the regulator.

Vaccination 363

Vaccination Vaccine Protein Clinical Trials 363

Pharmaceutical Technology

SEPTEMBER 8, 2022

Find the leading API biologics companies in contract marketing. Pharmaceutical Technology has listed some of the top API biologics companies in contract marketing based on our intel, insights and decades-long experience in the sector.

Gene 100

Gene Marketing Vaccination Vaccine 100

Pharmaceutical Technology

MARCH 31, 2023

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March.

Vaccination 277

Vaccination Vaccine Immune Response Antibody 277

Pharmaceutical Technology

JANUARY 19, 2023

The Korean Ministry of Food and Drug Safety (KMFDS) has granted expanded approval to Novavax partner SK bioscience for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use as a booster dose in adults aged 18 and above. Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain.

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

pharmaphorum

DECEMBER 9, 2021

AstraZeneca’s antibody cocktail for COVID-19, now called Evushield, has become the first drug in the class to be authorised for prevention of infection by the US FDA. The emergency use authorisation (EUA) for Evushield activates a 700,000 order for the antibody from the US government, worth upwards of $726 million.

Antibody 124

Antibody Immune Response Vaccination Vaccine 124

pharmaphorum

NOVEMBER 8, 2021

A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data. The rate of COVID-19 vaccination was balanced between the two groups. The rate of COVID-19 vaccination was balanced between the two groups.

Antibody 105

Antibody Vaccination Vaccine Immune Response 105

Pharmaceutical Technology

SEPTEMBER 2, 2022

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting expanded conditional marketing authorization (CMA) for Novavax ’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), as a booster in adults aged 18 years and above.

Vaccination 147

Vaccination Vaccine Trials Clinical Trials 147

pharmaphorum

DECEMBER 5, 2022

Valneva has moved a step closer to its goal of becoming the first company to file for approval of a vaccine against chikungunya virus in the US after reporting new clinical data today. Valneva estimates that the global market for vaccines against chikungunya could exceed $500 million annually by 2032.

Vaccination 98

Vaccination Vaccine Antibody Allergies 98

pharmaphorum

AUGUST 12, 2022

Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, because the government has shelved plans to offer treatment with AstraZeneca’s antibody therapy Evusheld. — Kidney Care UK (@kidneycareuk) August 12, 2022.

Antibody 145

Antibody Vaccination Vaccine Drugs 145

XTalks

FEBRUARY 5, 2024

In the first year of the respiratory syncytial virus (RSV) vaccine battle, GlaxoSmithKline’s (GSK) Arexvy emerged as the winner over Pfizer’s Abrysvo. GSK declared Arexvy to be a blockbuster in its first year on the market after higher-than-expected sales. The company has reported the vaccine to be 83.7 billion or £1.2

Vaccination 59

Vaccination Vaccine Marketing Sales 59

World of DTC Marketing

MARCH 16, 2021

IN BRIEF: As a marketer, most of us, like a Jungian archetype, are true Communicators. As a pharma marketer who has worked in many other therapeutic categories and recently on a Covid launch, I have become acutely aware of the interaction between national poles and the on-the-ground sentiment I have observed.

Marketing 180

Marketing Vaccination Vaccine RNA 180

BioSpace

SEPTEMBER 17, 2020

Roche launched its Elecsys Anti-SARS-CoV-2 S antibody test for markets that accept the CE Mark.

Antibody 120

Antibody Vaccination Vaccine Marketing 120

BioTech 365

JANUARY 14, 2022

Outlook on the Biologics Contract Manufacturing Global Market to 2031 – Focus on Monoclonal Antibodies, Recombinant Proteins, Vaccines and Molecular Therapy – ResearchAndMarkets.com Outlook on the Biologics Contract Manufacturing Global Market to 2031 – Focus on Monoclonal Antibodies, Recombinant Proteins, … Continue reading (..)

Contract Manufacturing 40

Contract Manufacturing Protein Antibody Manufacturing 40

pharmaphorum

NOVEMBER 6, 2022

The antibody-based drug has been cleared by the European Commission with a broad label, covering both full-term and pre-term babies and those with a range of health conditions that could make the vulnerable to RSV, said the two pharma groups in a statement.

Antibody 64

Antibody Vaccination Vaccine Sales 64

BioTech 365

MARCH 29, 2021

Global Pharmaceuticals Market Report 2021: Monoclonal Antibodies (MAbS); Therapeutic Proteins; Vaccines COVID-19 Impact and Recovery to 2030 – ResearchAndMarkets.com Global Pharmaceuticals Market Report 2021: Monoclonal Antibodies (MAbS); Therapeutic Proteins; Vaccines COVID-19 Impact and Recovery to 2030 – ResearchAndMarkets.com DUBLIN–(BUSINESS (..)

Protein 40

Protein Antibody Vaccination Vaccine 40

Pharmaceutical Technology

SEPTEMBER 19, 2022

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AstraZeneca ’s Evusheld (formerly AZD7442) for Covid-19 in the European Union (EU). Additionally, in the trial, the antibody cocktail was found to be well-tolerated.

In-Vitro 279

In-Vitro Antibody Vaccination Vaccine 279

pharmaphorum

JULY 1, 2024

AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP).The

Vaccination 115

Vaccination Vaccine Antibody Marketing 115

Pharmaceutical Technology

SEPTEMBER 15, 2022

The increase in the production of biological drugs such as vaccines, gene and cell therapies, and monoclonal antibodies, is increasing the volume of injectable drug products in the global healthcare market. Discover the top commercial dose injectables companies in contract marketing.

Marketing 130

Marketing Containment Production Sales 130

pharmaphorum

JANUARY 13, 2022

Preliminary data from an ongoing trial of AstraZeneca’s COVID-19 vaccine Vaxzevria has shown that a booster dose stimulates an increase in antibodies against Omicron, as well as other variants of the virus, including Alpha, Beta, Delta, and Gamma. billion doses administered. billion doses administered.

Antibody 97

Antibody Immune Response Vaccination Vaccine 97

Pharmaceutical Technology

AUGUST 23, 2022

5-adapted bivalent vaccine for Covid-19 in people aged 12 years and above. 1-adapted vaccine. The FDA also sought the vaccine’s pre-clinical and manufacturing data for addressing the SARS-CoV-2 virus’ evolution. 5-adapted bivalent vaccine will be made readily available for shipping. 5-adapted bivalent vaccine.

Vaccination 130

Vaccination Vaccine Gene Therapy Protein 130

pharmaphorum

OCTOBER 5, 2021

AstraZeneca has sought emergency use authorisation for its antibody combination AZD7442, following trial results indicating it can prevent symptomatic COVID-19 infection when given to healthy patients. The post AZ files for emergency use of COVID-19 antibody combo in US appeared first on. Initial results from that study were negative.

Antibody 110

Antibody Immune Response Vaccination Vaccine 110

Roots Analysis

FEBRUARY 23, 2024

Imagine a world where scientists work together to create special “soldiers” in our bodies called antibodies. Sometimes, scientists ask for help from experts who are really good at finding and designing these antibodies. What are the steps involved in an antibody discovery project? These heroes help to fight diseases.

Antibody 40

Antibody Research Marketing Scientist 40

pharmaphorum

FEBRUARY 25, 2021

Pfizer/BioNTech’s mRNA vaccine against COVID is a technical marvel – but the ultra-cool temperatures required for storage and stability has been tricky to handle. The company announced a phase 1 trial is beginning of its nasal spray vaccine just as scientists in the UK said they are considering a similar approach.

Vaccination 111

Vaccination Vaccine Immune Response Trials 111

pharmaphorum

JULY 6, 2021

A peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer in a phase 2 trial. ” The anti-HER2 market is advancing rapidly however, with a new generation of drugs coming through the industry pipeline.

Vaccination 119

Vaccination Vaccine Trials Antibody 119

Pharmaceutical Technology

APRIL 10, 2023

It will also be used for the treatment of people who are not likely to have an adequate immune response to Covid-19 vaccination or for people who are not recommended for Covid-19 vaccination. Evusheld (formerly AZD7442) is a combination of two long-acting antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061).

Immune Response 264

Immune Response Antibody Vaccination Vaccine 264

pharmaphorum

SEPTEMBER 16, 2022

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections. Both vaccines are also being tested in older adults. The post CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevention appeared first on.

Antibody 59

Antibody Vaccination Vaccine Marketing 59

XTalks

AUGUST 30, 2024

This blog highlights the top 10 largest publicly traded pharma and biotech companies by market capitalization in 2024 , showcasing their influence and contributions to global health. Johnson & Johnson (JNJ) Market Capitalization: $402.1 Novo Nordisk (NVO) Market Capitalization: $377.2 MRK) Market Capitalization: $280.4

Marketing 78

Marketing Production Sales Antibody 78

Fierce Pharma

MARCH 25, 2024

The four years since the start of the COVID-19 pandemic have yielded many advances against the coronavirus, including Moderna and Pfizer’s groundbreaking mRNA vaccines. |

Antibody 97

Antibody Vaccination Vaccine Marketing 97

Roots Analysis

OCTOBER 25, 2023

On 23 October 2023, Merck announced a development agreement for Daiichi Sankyo’s clinical-phase antibody-drug conjugate, namely patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd), targeting cancer. According to Roots Analysis, the antibody drug conjugate market is estimated to be worth $7.72

Antibody 40

Antibody Development Drugs Marketing 40

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. This is the focus of vaccines in development and convalescent plasma therapy.

Antibody 52

Antibody Vaccination Vaccine In-Vitro 52

XTalks

JANUARY 31, 2022

COVID-19 vaccine makers Pfizer/BioNTech and Moderna have both commenced trials for their new variant-specific vaccines targeting omicron. Pfizer and BioNTech have started to enroll participants in a study that will evaluate the new version of their COVID-19 vaccine that targets the omicron variant of SARS-CoV-2.

Vaccination 85

Vaccination Vaccine Trials Antibody 85

pharmaphorum

JANUARY 31, 2022

Daiichi Sankyo has stepped up its efforts to bring a Japanese COVID-19 vaccine to patients, starting a new clinical trial of its mRNA-based candidate DS-5670 that focuses on its use as a booster dose. The Japanese group says it hopes to complete clinical development of the vaccine and bring it to market in Japan before the end of the year.

Marketing 90

Marketing Vaccination Vaccine Antibody 90

Pharmaceutical Technology

FEBRUARY 1, 2023

Pharmaceutical companies have been working on developing vaccines and other prophylactics for respiratory syncytial virus (RSV) since its discovery in 1956. Despite strong efforts and scientific advances, a safe and effective vaccine for RSV has yet to be approved for any patient population.

Vaccination 162

Vaccination Vaccine Antibody Protein 162

pharmaphorum

MARCH 9, 2021

Last year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – and now it is ready to begin clinical development of a potential treatment that could be effective against emerging COVID-19 variants. ExeVir is not the first company to spin out of VIB to focus on camelid antibodies.

Antibody 98

Antibody Life Science Scientist Development 98

pharmaphorum

MAY 11, 2022

A pooled analysis of data for AstraZeneca and Sanofi’s respiratory syncytial virus (RSV) antibody nirsevimab has concluded that the drug is almost 80% effective at preventing lower respiratory tract infections caused by the pathogen. versus placebo. versus placebo.

Antibody 64

Antibody Vaccination Vaccine Trials 64